6K9

(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1~3,32~.1~3,33~.1~6,9~.1~12,16~.0~18,22~.0~29,36~.0~31,35~]hentetracontan-24-one (non-preferred name)

Created: 2016-04-21
Last modified:  2016-06-29

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count111
Chiral Atom Count19
Bond Count119
Aromatic Bond Count0
2D diagram of 6K9
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1~3,32~.1~3,33~.1~6,9~.1~12,16~.0~18,22~.0~29,36~.0~31,35~]hentetracontan-24-one (non-preferred name)
Systematic Name (OpenEye OEToolkits)n/a
FormulaC40 H59 N O11
Molecular Weight729.897
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs12.01C31C9OC2C1OC5(C2)OC9C4C(O3)CCC(O4)CC(CC8C(CC7C(/C(CC(CCC6C(\CC(CC5)O6)=C)O7)C)=C)OC(C8OC)CC(CN)O)=O
SMILESCACTVS3.385CO[CH]1[CH](C[CH](O)CN)O[CH]2C[CH]3O[CH](CC[CH]4O[CH](CC[C]56C[CH]7O[CH]8[CH](O[CH]9CC[CH](CC(=O)C[CH]12)O[CH]9[CH]8O5)[CH]7O6)CC4=C)C[CH](C)C3=C
SMILESOpenEye OEToolkits2.0.4CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O
Canonical SMILESCACTVS3.385 CO[C@H]1[C@@H](C[C@H](O)CN)O[C@H]2C[C@H]3O[C@@H](CC[C@@H]4O[C@@H](CC[C@@]56C[C@H]7O[C@@H]8[C@@H](O[C@H]9CC[C@H](CC(=O)C[C@H]12)O[C@@H]9[C@@H]8O5)[C@H]7O6)CC4=C)C[C@@H](C)C3=C
Canonical SMILESOpenEye OEToolkits2.0.4 C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
InChIInChI1.03 InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
InChIKeyInChI1.03 UFNVPOGXISZXJD-JBQZKEIOSA-N

Drug Info: DrugBank

DrugBank IDDB08871 
NameEribulin
Groups
  • investigational
  • approved
DescriptionEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].
Synonyms
  • Eribulin mesylate
  • Eribulina
  • Eribulin
Brand Names
  • Eribulin Mesylate Injection
  • Eribulin Mesylate
  • Halaven
  • Nat-eribulin
  • Mevlyq
IndicationFor the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Ethers
  • Ethers, Cyclic
  • Immunosuppressive Agents
ATC-CodeL01XX41
CAS number253128-41-5

Drug Targets

NameTarget SequencePharmacological ActionActions
Tubulin beta-1 chainMREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVY...unknowninhibitor
Apoptosis regulator Bcl-2MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...unknown
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1683590
PubChem 11354606
ChEMBL CHEMBL1683590
ChEBI CHEBI:63587